Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

New genetic evidence strengthens link between role of dietary fats with colon cancer progression

Scientists have shown new genetic evidence that could strengthen the link between the role of dietary fats with colon cancer progression.

22 Apr 2014

New study identifies potential target for colorectal cancer treatment

A new study identifies a molecule that is a probable driving force in colorectal cancer and suggests that the molecule could be an important target for colorectal cancer treatment and a valuable biomarker of tumor progression.

15 Apr 2014

Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

Scientists from INRA and INSERM (France) in collaboration with scientists from McMaster University (Canada) and the Ecole polytechnique fédérale of Zurich (Switzerland) have shown that Elafin, a human protein, plays a key role against the inflammatory reaction typical of celiac disease (gluten intolerance).

8 Apr 2014

New insights provide novel therapeutic approach against cancer

A major discovery that brings a new drug target to the increasingly exciting landscape of cancer immunotherapy was published yesterday by researchers from La Jolla Institute for Allergy and Immunology and their collaborators from other institutes.

7 Apr 2014

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD), which means there is chronic inflammation and ulceration in the lining of the digestive tract, usually in the large intestine.

26 Mar 2014

ASU scientist selected as 2014 recipient of Lifetime Achievement Award

Roy Curtiss III, a scientist at the Biodesign Institute at Arizona State University, has been selected as the 2014 recipient of the Lifetime Achievement Award from the American Society for Microbiology.

26 Mar 2014

Study suggests effective therapeutics for IBD may hinge on targeting GM-CSF axis

The protein GM-CSF plays a critical role in maintaining immune tolerance in the gut, with defects in the protein increasing the susceptibility to inflammatory bowel diseases (IBD), according to a new mouse study by a team of researchers from the Icahn School of Medicine at Mount Sinai.

17 Mar 2014

Gut bacteria and blood cell development relationship helps immune system fight infection

The human relationship with microbial life is complicated. At almost any supermarket, you can pick up both antibacterial soap and probiotic yogurt during the same shopping trip.

13 Mar 2014

SCCA experts develop helpful tool to simplify colon cancer prevention, screening guidelines

Colon cancer will take more than 50,000 American lives in 2014 making it the second leading cause of cancer-related deaths, according to the American Cancer Society.

11 Mar 2014

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012.

6 Mar 2014

UCLA experts offer tips to help protect colon health

With colorectal cancer the second leading cause of cancer death, it's a great time to take a look at the health of your colon.

6 Mar 2014

Altheus Therapeutics completes dosing of ZA201 in Phase 2 trial of Zoenasa for ulcerative colitis

Altheus Therapeutics, Inc., announced completion of dosing in ZA201, a double-blind, active-controlled Phase 2 trial evaluating the efficacy and safety of Zoenasa® Rectal Gel versus mesalamine enema in 120 patients with left-sided ulcerative colitis.

27 Feb 2014

Ulcerative colitis patients not satisfied with current treatments according to new study

Patients with a serious type of inflammatory bowel disease, ulcerative colitis, are not satisfied with their current treatments and the majority do not have their disease under control, according to new research released today at the 9th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Copenhagen. The majority (87.2 per cent) of the 250 patients with moderate to severe ulcerative colitis who were being treated with standard therapies failed to achieve control of their disease – defined either as going into remission or not having needed to use corticosteroid medications in the previous two months.1

21 Feb 2014

Researchers identify new type of regulatory blood cells that can combat brain inflammation

Hyperactivity of our immune system can cause a state of chronic inflammation. If chronic, the inflammation will affect our body and result in disease. In the devastating disease multiple sclerosis, hyperactivity of immune cells called T-cells induce chronic inflammation and degeneration of the brain. Researchers at BRIC, the University of Copenhagen, have identified a new type of regulatory blood cells that can combat such hyperactive T-cells in blood from patients with multiple sclerosis. By stimulating the regulatory blood cells, the researchers significantly decreased the level of brain inflammation and disease in a biological model.

17 Feb 2014

Elusive progenitor cells that give rise to ILCs identified in fetal liver and bone marrow of mice

The elusive progenitor cells that give rise to innate lymphoid cells-a recently discovered group of infection-fighting white blood cells-have been identified in fetal liver and adult bone marrow of mice, researchers from the University of Chicago report early online in the journal Nature.

14 Feb 2014

Alvogen launches Inflectra into Central and Eastern Europe

Alvogen, the multinational pharmaceuticals company, today announced the launch of Inflectra (Infliximab) into Central and Eastern Europe. Inflectra, Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

13 Feb 2014

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery."

12 Feb 2014

Telephone communication in IBD care helps to identify patients at risk of high-cost medical interventions

A comprehensive analysis of patient telephone records at an inflammatory bowel disease (IBD) clinic revealed that 15 percent of patients account for half of all calls to the clinic. Forty-two percent of frequent-caller patients also were seen in the emergency department or hospitalized within the following year.

10 Feb 2014

Blood disorder medicines could be used for treating stomach and bowel cancer

Stomach and bowel cancer, two of the most common cancers worldwide, could be treated with a class of medicines that are currently used to treat a blood disorder, a Melbourne research team has discovered.

5 Feb 2014

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine).

30 Jan 2014

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

New genetic evidence strengthens link between role of dietary fats with colon cancer progression

New study identifies potential target for colorectal cancer treatment

Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

New insights provide novel therapeutic approach against cancer

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

ASU scientist selected as 2014 recipient of Lifetime Achievement Award

Study suggests effective therapeutics for IBD may hinge on targeting GM-CSF axis

Gut bacteria and blood cell development relationship helps immune system fight infection

SCCA experts develop helpful tool to simplify colon cancer prevention, screening guidelines

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

UCLA experts offer tips to help protect colon health

Altheus Therapeutics completes dosing of ZA201 in Phase 2 trial of Zoenasa for ulcerative colitis

Ulcerative colitis patients not satisfied with current treatments according to new study

Researchers identify new type of regulatory blood cells that can combat brain inflammation

Elusive progenitor cells that give rise to ILCs identified in fetal liver and bone marrow of mice

Alvogen launches Inflectra into Central and Eastern Europe

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Telephone communication in IBD care helps to identify patients at risk of high-cost medical interventions

Blood disorder medicines could be used for treating stomach and bowel cancer

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in